RESMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.9 AUD | +4.36% |
|
+4.84% | +17.53% |
| Jul. 01 | ResMed Inc.(NYSE:RMD) added to Russell 1000 Dynamic Index | CI |
| Jul. 01 | ResMed Inc.(NYSE:RMD) added to Russell Midcap Value Index | CI |
| Sales 2024 * | 4.68B 6.9B | Sales 2025 * | 5.03B 7.42B | Capitalization | 30.09B 44.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.02B 1.51B | Net income 2025 * | 1.24B 1.83B | EV / Sales 2024 * | 6.56 x |
| Net Debt 2024 * | 605M 892M | Net cash position 2025 * | 333M 491M | EV / Sales 2025 * | 5.91 x |
| P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
24.8
x | Employees | 10,140 |
| Yield 2024 * |
0.96% | Yield 2025 * |
1.05% | Free-Float | 76.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on ResMed Inc.
More recommendations
More news
| 1 day | +4.36% | ||
| 1 week | +4.84% | ||
| Current month | +2.75% | ||
| 1 month | -5.77% | ||
| 3 months | +2.40% | ||
| 6 months | +13.04% | ||
| Current year | +17.53% |
1 week
28.16
29.90
1 month
27.1332.16
Current year
24.4433.50
1 year
21.1434.27
3 years
21.1440.79
5 years
17.3140.79
10 years
5.1940.79
| Managers | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
Brett Sandercock
DFI | Director of Finance/CFO | 57 | 97-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Ron Taylor
BRD | Director/Board Member | 76 | 04-12-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 29.9 | +4.36% | 1,924,607 |
| 24-07-11 | 28.65 | +0.92% | 949,440 |
| 24-07-10 | 28.39 | -0.87% | 2,034,428 |
| 24-07-09 | 28.64 | -0.49% | 1,262,256 |
| 24-07-08 | 28.78 | +0.91% | 737,475 |
Delayed Quote Australian S.E., July 12, 2024 at 02:10 am EDT
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
2024-08-01
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
204.8
USD
Average target price
220.9
USD
Spread / Average Target
+7.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.26% | 209B | |
| +6.55% | 183B | |
| +31.66% | 158B | |
| +34.32% | 114B | |
| +5.13% | 67.29B | |
| +19.33% | 54.83B | |
| -3.30% | 46.88B | |
| -4.84% | 38.58B | |
| +3.83% | 36.65B |
- Stock Market
- Equities
- RMD Stock
- RMD Stock
